On December 17, Kanghua Biotech (300841) announced that its hexavalent recombinant Norovirus vaccine (Pichia pastoris) has received a clinical trial approval notification. The vaccine developed by the company has recently been issued a "Clinical Trial Approval Notification" by the National Medical Products Administration, granting permission to conduct clinical trials. This vaccine is intended to prevent Norovirus infections and the acute gastroenteritis they cause, with the theoretical ability to prevent over 90% of related infections.

The receipt of the clinical trial approval notification will not have a significant impact on the company's short-term financial status and operating performance. The company will actively promote clinical research for this product; if successful, it will enrich the company's product portfolio, enhance its core competitiveness and market position, thereby increasing profitability. However, the vaccine development process is lengthy and technically challenging, posing certain research risks and uncertainties that investors should consider cautiously.

In the first three quarters of 2024, Kanghua Biotech reported revenues of 1.06 billion yuan and a net profit attributable to shareholders of 406 million yuan.

https://finance.eastmoney.com/a/202412173270729285.html